Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.
复制标题
DOI：
10.4103/0971-5851.151781
复制
发表时间：
2015-01
期刊：
影响因子：
--
通讯作者：
Saikia BJ
中科院分区：
文献类型：
--
作者：
Baruah U;Barmon D;Kataki AC;Deka P;Hazarika M;Saikia BJ
晚期卵巢癌患者预后差，尽管最好的护理。原发性减瘤手术已成为晚期卵巢癌的标准治疗方法；然而，各种研究表明，它与高死亡率和发病率有关。一些研究讨论了晚期卵巢癌患者新辅助化疗的益处。本研究旨在评估2007年1月至2009年12月间期减容手术（IDS）患者的生存统计数据。在2007年1月至2009年12月期间，我们选择了104例在我们研究所因IIIC期或IV期晚期上皮性卵巢癌接受IDS治疗的患者进行回顾性分析。在紫杉醇（175 mg/m2）和卡铂（5-6曲线下面积）化疗3 - 5个疗程后尝试IDS。总生存期（OS）和无进展生存期（PFS）从现有文献中进行初步减积研究的结果进行比较。采用Kaplan-Meier法估计OS和PFS率。采用IBM SPSS Statistics 19对结果进行统计学分析。中位OS为26个月，中位PFS为18个月。在多变量分析中，我们发现OS和PFS都受到减积期和减积程度的影响。新辅助化疗，随后手术细胞减少是一个很有前途的治疗策略，为管理晚期上皮性卵巢癌。
Patients with advanced ovarian cancer have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced ovarian cancer; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in patients with advanced ovarian cancer. This study aims to evaluate the survival statistics of the patients who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009. During the period from January 2007 to December 2009, a retrospective analysis of 104 patients who underwent IDS for stage IIIC or IV advanced epithelial ovarian cancer at our institute were selected for the study. IDS was attempted after three to five courses of chemotherapy with paclitaxal (175 mg/m2 ) and carboplatin (5-6 of area under curve). Overall survival (OS) and progression free survival (PFS) were compared with results of primary debulking study from existing literature. OS and PFS rates were estimated by means of the Kaplan-Meier method. Results were statistically analyzed by IBM SPSS Statistics 19. The median OS was 26 months and the median PFS was 18 months. In multivariate analysis it was found that both OS and PFS was affected by the stage, and extent of debulking. Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.